Bevacizumab and ovarian cancer

Drugs of Today

Volumn 47, Issue 9, 2011, Pages 669-681

  Lai, G G Y ^a   Penson, Richard T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; PACLITAXEL; TOPOTECAN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL ABSCESS; ANGINA PECTORIS; ANGIOGENESIS; BACKACHE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM FISTULA; DIVERTICULITIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EPISTAXIS; EXFOLIATIVE DERMATITIS; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GLIOBLASTOMA; HEADACHE; HEART INFARCTION; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; IMMUNOGENICITY; KIDNEY CARCINOMA; LACRIMATION DISORDER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; NEPHROTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; PROTEINURIA; RECTUM HEMORRHAGE; REVIEW; RHINITIS; SIDE EFFECT; TASTE DISCRIMINATION; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; TUMOR XENOGRAFT; VAGINA BLEEDING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INTERACTIONS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; PATIENT SELECTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80053934771     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.9.1673557     Document Type: Review

References (126)

1. American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society: Atlanta, GA 2010.
2. Cannistra, S.A. Cancer of the ovary. N Engl J Med 2004, 351(24): 2519-29.
3. Gore, M.E. Treatment of relapsed epithelial ovarian carcinoma. In: American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology: Alexandria, VA 2001.
4. Bookman, M.A., Brady, M.F., McGuire, W.P. et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009, 27(9): 1419-25.
5. Folkman, J., Watson, K., Ingber, D., Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339(6219): 58-61. (Pubitemid 19115892)
6. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82(1): 4-6. (Pubitemid 20020880)
7. Hicklin, D.J., Ellis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23(5): 1011-27. (Pubitemid 46202320)
8. Ferrara, N., Kerbel, R.S. Angiogenesis as a therapeutic target. Nature 2005, 438(7070): 967-74. (Pubitemid 43093963)
9. Boss, E.A., Massuger, L.F., Thomas, C.M., Geurts-Moespot, A., Boonstra, H., Sweep, C.G. Vascular endothelial growth factor in ovarian cyst fluid. Cancer 2001, 91(2): 371-7. (Pubitemid 32099239)
10. Jain, R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7(9): 987-9. (Pubitemid 32937367)
11. Carmeliet, P., Jain, R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801): 249-57.
12. Brown, M.R., Blanchette, J.O., Kohn, E.C. Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol 2000, 14(6): 901-18. (Pubitemid 32123680)
13. Ramakrishnan, S., Subramanian, I.V., Yokoyama, Y., Geller, M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005, 8(2): 169-82. (Pubitemid 41712846)
14. Burger, R.A. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007, 25(20): 2902-8. (Pubitemid 47123154)
15. Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219(4587): 983-5.
16. Dvorak, H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20(21): 4368-80. (Pubitemid 35266299)
17. Ferrara, N., Gerber, H.P., LeCouter, J. The biology of VEGF and its receptors. Nat Med 2003, 9(6): 669-76. (Pubitemid 36749215)
18. Chen, H., Ye, D., Xie, X., Chen, B., Lu, W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 2004, 94(3): 630-5. (Pubitemid 39194453)
19. Santin, A.D., Hermonat, P.L., Ravaggi, A., Cannon, M.J., Pecorelli, S., Parham, G.P. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 1999, 20(3): 177-81. (Pubitemid 29286483)
20. Hazelton, D.A., Hamilton, T.C. Vascular endothelial growth factor in ovarian cancer. Curr Oncol Rep 1999, 1(1): 59-63.
21. Hartenbach, E.M., Olson, T.A., Goswitz, J.J., Mohanraj, D., Twiggs, L.B., Carson, L.F., Ramakrishnan, S. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997, 121(2): 169-75. (Pubitemid 28008916)
22. Goodheart, M.J., Ritchie, J.M., Rose, S.L., Fruehauf, J.P., De Young, B.R., Buller, R.E. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 2005, 11(10): 3733-42. (Pubitemid 40685590)
23. Hefler, L.A., Mustea, A., Konsgen, D. et al. Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 2007, 13(3): 898-901. (Pubitemid 46340365)
24. Cooper, B.C., Ritchie, J.M., Broghammer, C.L. et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 2002, 8(10): 3193-7. (Pubitemid 35155030)
25. Byrne, A.T., Ross, L., Holash, J. et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9(15): 5721-8. (Pubitemid 37499496)
26. Presta, L.G., Chen, H., O'Connor, S.J. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57(20): 4593-9. (Pubitemid 27441066)
27. Kim, K.J., Li, B., Houck, K., Winer, J., Ferrara, N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992, 7(1): 53-64.
28. Mesiano, S., Ferrara, N., Jaffe, R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998, 153(4): 1249-56. (Pubitemid 28465848)
29. Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2(10): 795-803. (Pubitemid 37328914)
30. Data on file. Genentech, Inc., South San Francisco, CA: 2002.
31. Lin, Y.S., Nguyen, C., Mendoza, J.L., Escandon, E., Fei, D., Meng, Y.G., Modi, N.B. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999, 288(1): 371-8. (Pubitemid 29113511)
32. Gordon, M.S., Margolin, K., Talpaz, M. et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19(3): 843-50. (Pubitemid 32119100)
33. Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21(1): 60-5.
34. Cobleigh, M.A., Langmuir, V.K., Sledge, G.W. et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003, 30(5 Suppl. 16): 117-24. (Pubitemid 37433402)
35. DeVore, R., Fehrenbacher, L., Herbst, R. A randomized phase II trial comparing rHumAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage III/IV NSCLC. Proc Am Soc Clin Oncol [36th Annu Meet Amer Soc Clin Oncol (May 20-23, New Orleans) 2000] 2000, 19: Abst 1896.
36. Bergsland, E., Dickler, M.N. Maximizing the potential of bevacizumab in cancer treatment. Oncologist 2004, 9(Suppl. 1): 36-42. (Pubitemid 38747846)
37. Lu, J.F., Bruno, R., Eppler, S., Novotny, W., Lum, B., Gaudreault, J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008, 62(5): 779-86.
38. Hsei, V., Novotny, W., Margolin, K. et al. Population pharmacokinetic (PK) analysis of bevacizumab (BV) in cancer subjects. Proc Am Soc Clin Oncol [37th Annu Meet Amer Soc Clin Oncol (May 12-15, San Francisco) 2001] 2001, 20(Part 1): Abst 272.
39. Gaudreault, J., Lieberman, G., Kabbinavar, F. et al. Pharmacokinetics (PK) of bevacizumab (BV) in colorectal cancer. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 6-10, Orlando) 2001] 2001, 69(2): Abst PI-98.
40. Gaudreault, J., Greig, G., Cosson, V., Gupta, M., Jumbe, N., Hooker, A. Population pharmacokinetics of bevacizumab. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 26(15, Suppl.): Abst 14570.
41. Avastin [package insert]. Genentech, Inc., South San Francisco, CA: 2009.
42. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v40, 2010.
43. Burger, R.A., Sill, M.W., Monk, B.J., Greer, B.E., Sorosky, J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25(33): 5165-71. (Pubitemid 350237599)
44. Cannistra, S.A., Matulonis, U.A., Penson, R.T. et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25(33): 5180-6. (Pubitemid 350232248)
45. Wright, J.D., Secord, A.A., Numnum, T.M. et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer 2008, 18(3): 400-6. (Pubitemid 351668295)
46. Wright, J.D., Hagemann, A., Rader, J.S. et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 2006, 107(1): 83-9. (Pubitemid 43939034)
47. Cohn, D.E., Valmadre, S., Resnick, K.E., Eaton, L.A., Copeland, L.J., Fowler, J.M. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006, 102(2): 134-9. (Pubitemid 44056263)
48. Garcia, A.A., Hirte, H., Fleming, G. et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008, 26(1): 76-82.
49. Micha, J.P., Goldstein, B.H., Rettenmaier, M.A. et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007, 17(4): 771-6. (Pubitemid 47063333)
50. Rose, P., Drake, R., Braly, P. et al. Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 5546.
51. Hapani, S., Chu, D., Wu, S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009, 10(6): 559-68.
52. Gordon, M.S., Cunningham, D. Managing patients treated with bevacizumab combination therapy. Oncology 2005, 69(Suppl. 3): 25-33. (Pubitemid 41680950)
53. Hedrick, E., Kozloff, M., Hainsworth, J.D. et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BriTE). J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 2-6, Atlanta) 2006, 24(18S): Abst 3536.
54. Han, E.S., Monk, B.J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007, 105(1): 3-6. (Pubitemid 46441477)
55. Hurwitz, H., Fehrenbacher, L., Novotny, W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23): 2335-42. (Pubitemid 38702844)
56. Sandler, A., Gray, R., Perry, M.C. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24): 2542-50. (Pubitemid 44917502)
57. Miller, K., Wang, M., Gralow, J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26): 2666-76.
58. Escudier, B., Pluzanska, A., Koralewski, P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370(9605): 2103-11. (Pubitemid 350296300)
59. Allegra, C.J., Yothers, G., O'Connell, M.J. et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009, 27(20): 3385-90.
60. Reck, M., von Pawel, J., Zatloukal, P. et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27(8): 1227-34.
61. Saltz, L.B., Clarke, S., Diaz-Rubio, E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26(12): 2013-9.
62. Giantonio, B.J., Catalano, P.J., Meropol, N.J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25(12): 1539-44. (Pubitemid 46733080)
63. Miller, K.D., Chap, L.I., Holmes, F.A. et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23(4): 792-9. (Pubitemid 46224178)
64. Scappaticci, F.A., Skillings, J.R., Holden, S.N. et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99(16): 1232-9. (Pubitemid 47299901)
65. McGonigle, K.F., Muntz, H.G., Vuky, J. et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. Cancer 2011, 117(16): 3731-40.
66. Nimeiri, H.S., Oza, A.M., Morgan, R.J. et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008, 110(1): 49-55.
67. Glusker, P., Recht, L., Lane, B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354(9): 980-2.
68. Spigel, D., Hainsworth, J., Farley, C. et al. Tracheoesophageal (TE) fistula development in a phase II trial of concurrent chemoradiation (CRT) and bevacizumab in limited-stage small-cell lung cancer (LS-SCLC). J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 26(15, Suppl.): Abst 7554.
69. Scappaticci, F.A., Fehrenbacher, L., Cartwright, T. et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005, 91(3): 173-80. (Pubitemid 41254420)
70. Denlinger, C.S., Blanchard, R., Xu, L. et al. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009, 65(1): 97-105.
71. Horita, Y., Yamada, Y., Hirashima, Y., Kato, K., Nakajima, T., Hamaguchi, T., Shimada, Y. Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy. Cancer Chemother Pharmacol 2010, 65(3): 467-71.
72. Johnson, D.H., Fehrenbacher, L., Novotny, W.F. et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22(11): 2184-91. (Pubitemid 41095154)
73. Burger, R.A., Brady, M.F., Bookman, M.A. et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(18, Suppl.): Abst LBA1.
74. Perren, T., Swart, A.M., Pfisterer, J. et al. ICON 7: A phase III randomized gynecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab versus chemotherapy alone in women with newly diagnosed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. 35th Eur Soc Med Oncol (ESMO) Congr (Oct 8-12, Milan) 2010, Abst LBA4.
75. Kristensen, G., Perren, T., Qian, W. et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(15, Suppl.): Abst LBA5006.
76. Karihtala, P., Maenpaa, J., Turpeenniemi-Hujanen, T., Puistola, U. Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial. Anticancer Res 2010, 30(3): 1001-6.
77. Campos, S., Atkinson, T., Berlin, S. et al. STAC: a phase II study of carboplatin/paclitaxel/bevacizumab followed by randomization to either bevacizumab alone or erlotinib and bevacizumab in the upfront management of patients with ovarian, fallopian tube or peritoneal cancer. Gynecol Oncol [42nd Annu Meet Soc Gynecol Oncol (March 6-9, Orlando) 2011] 2011, 120(Suppl. 1): Abst 181.
78. Penson, R.T., Dizon, D.S., Cannistra, S.A. et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010, 28(1): 154-9.
79. Krasner, C.N., Seiden, M., Roche, M.R. et al. Tolerability and pharmacokinetics of intraperitoneal carboplatin and paclitaxel with intravenous bevacizumab. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 5037.
80. Konner, J., Grabon, D., Pezzulli, S. et al. A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 5539.
81. McMeekin, D.D., Lanneau, G., Curiel, J., Moore, K., Walker, J.L., Mannel, R. Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers. J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 5540.
82. Bevacizumab and intravenous or intraperitoneal chemotherapy in treating patients with stage II, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer (NCT00951496). ClinicalTrials.gov Web site, Accessed September 15, 2011.
83. Carboplatin and paclitaxel with or without bevacizumab after surgery in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer (NCT00565851). ClinicalTrials.gov Web site, Accessed September 15, 2011.
84. A study of carboplatin and gemcitabine plus bevacizumab in patients with ovary, peritoneal, or fallopian tube carcinoma (OCEANS) (NCT00434642). ClinicalTrials.gov Web site, Accessed September 15, 2011.
85. Aghajanian, C., Finkler, N.J., Rutherford, T. et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(15 Suppl.): Abst LBA5007.
86. Smerdel, M.P., Steffensen, K.D., Waldstrom, M., Brandslund, I., Jakobsen, A. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol 2010, 118(2): 167-71.
87. Monk, B.J., Han, E., Josephs-Cowan, C.A., Pugmire, G., Burger, R.A. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006, 102(2): 140-4. (Pubitemid 44056265)
88. Sanchez-Munoz, A., Mendiola, C., Perez-Ruiz, E. et al. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology 2010, 79(1-2): 98-104.
89. Matulonis, U.A., Pereira, L., Lee, H. et al. Sequential angiogenic blockade for the treatment of recurrent ovarian cancer. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 5083.
90. Kikuchi, Y., Kouta, H., Kikuchi, R. et al. Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer. J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 5547.
91. Muggia, F., Boyd, L., Liebes, L. et al. Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results. J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 5548.
92. Verschraegen, C., Muller, C., Rutledge, T., Arias-Pulido, H., Smith, H., Parise, S., Muggia, F. Preliminary efficacy and safety of pegylated lipsomal doxorubicin and bevacizumab in patients with platinum resistant or intolerant ovarian cancer: Initial results of a phase 2 trial. Intl Gynecol Cancer Soc 12th Bien Meet (Oct 25-28, Bangkok) 2008, Abst 2008-1558.
93. Tillmanns, T., Lowe, M., Schwartzberg, L., Walker, M., Stepanski, E. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 5009.
94. Wenham, R., LaPolla, J., Hui-Yi, L. et al. Phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecol Oncol [42nd Annu Meet Soc Gynecol Oncol (March 6-9, Orlando) 2011] 2011, 120(Suppl. 1): Abst 192.
95. Hurt, J., Backes, F., Rheaume, S., et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated, recurrent epithelial ovarian cancer. Gynecol Oncol [41st Annu Meet Soc Gynecol Oncol (March 10-17, San Francisco) 2010] 2010, 116(3, Suppl.): Abst 120.
96. Asmane, I., Guastalla, J.P., Meeus, P. et al. Feasibility of bevacizumab (BEV) plus chemotherapy in heavily pretreated ovarian cancer (OC) patients (pts): A retrospective study. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst e15509.
97. Bevis, K.S., Numnum, T.M., Shipman, K.A., Makhija, S., Barnes, M.N., Straughn, J. The efficacy and toxicity of bevacizumab plus gemcitabine in patients with recurrent ovarian cancer. Gynecol Oncol [39th Annu Meet Soc Gynecol Oncol (March 9-12, Tampa) 2008] 2008, 108(3, Suppl. 1): S119.
98. Richardson, D.L., Backes, F.J., Seamon, L.G. et al. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 2008, 111(3): 461-6.
99. Eisenhauer, E., Zanagnolo, V., Cohn, D.E. et al. A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer. Gynecol Oncol [42nd Annu Meet Soc Gynecol Oncol (March 6-9, Orlando) 2011] 2011, 120(Suppl. 1): Abst 69.
100. Chambers, S.K., Clouser, M.C., Baker, A.F. et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 2010, 16(21): 5320-8.
101. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology - Ovarian Cancer 2011.
102. Jubb, A.M., Harris, A.L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010, 11(12): 1172-83.
103. Chun, Y.S., Vauthey, J.N., Boonsirikamchai, P. et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009, 302(21): 2338-44.
104. Eisenhauer, E.A., Therasse, P., Bogaerts, J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2): 228-47.
105. Baar, J., Silverman, P., Lyons, J. et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res 2009, 15(10): 3583-90.
106. Zweifel, M., Padhani, A.R. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging 2010, 37(Suppl. 1): S164-82.
107. Wedam, S.B., Low, J.A., Yang, S.X. et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006, 24(5): 769-77. (Pubitemid 46622044)
108. .Thukral, A., Thomasson, D.M., Chow, C.K. et al. Inflammatory breast cancer: dynamic contrast-enhanced MRin patients receiving bevacizumab-initial experience. Radiology 2007, 244(3): 727-35. (Pubitemid 47292083)
109. Zhu, A.X., Meyerhardt, J.A., Blaszkowsky, L.S. et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010, 11(1): 48-54.
110. Chen, W., Delaloye, S., Silverman, D.H. et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007, 25(30): 4714-21. (Pubitemid 350086472)
111. Bast, R.C., Jr., Feeney, M., Lazarus, H., Nadler, L.M., Colvin, R.B., Knapp, R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981, 68(5): 1331-7. (Pubitemid 12235035)
112. Einhorn, N., Sjovall, K., Knapp, R.C., Hall, P., Scully, R.E., Bast, R.C., Jr., Zurawski, V.R., Jr. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992, 80(1): 14-8.
113. Kang, S., Seo, S.S., Park, S.Y. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer. J Surg Oncol 2009, 100(3): 244-7.
114. Rustin, G.J., Quinn, M., Thigpen, T. et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004, 96(6): 487-8. (Pubitemid 38443654)
115. Bast, R.C., Jr., Xu, F.J., Yu, Y.H., Barnhill, S., Zhang, Z., Mills, G.B. CA 125: the past and the future. Int J Biol Markers 1998, 13(4): 179-87. (Pubitemid 29178546)
116. O'Cearbhaill, R.E., Zhou, Q., Iasonos, A. et al. CA125 response to bevacizumab in recurrent ovarian cancer. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 5077.
117. Willett, C.G., Duda, D.G., di Tomaso, E. et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009, 27(18): 3020-6.
118. Dowlati, A., Gray, R., Sandler, A.B., Schiller, J.H., Johnson, D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008, 14(5): 1407-12. (Pubitemid 351413922)
119. Bernaards, C., Hegde, P., Chen, D. et al. Circulating bascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 10519.
120. Zahiragic, L., Schliemann, C., Bieker, R. et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007, 21(6): 1310-2. (Pubitemid 46831824)
121. Shaked, Y., Bocci, G., Munoz, R. et al. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets 2005, 5(7): 551-9. (Pubitemid 41502566)
122. Mancuso, P., Colleoni, M., Calleri, A. et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006, 108(2): 452-9. (Pubitemid 44061341)
123. Dellapasqua, S., Bertolini, F., Bagnardi, V. et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008, 26(30): 4899-905.
124. Pivot, X., Verma, S., Thomssen, C. et al. Clinical benefit of bevacizumab plus first-line docetaxel in elderly patients with locally recurrent or metastatic breast cancer. J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 1094.
125. Robert, N.J., Dieras, V., Glaspy, J. et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for firstline treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 1005.
126. Cohn, D.E., Kim, K.H., Resnick, K.E., O'Malley, D.M., Straughn, J.M., Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011, 29(10): 1247-51.